In vitro, XBP1s overexpression in an ESR1+ breast cancer cell line increased levels of the pro-survival protein BCL-2 and decreased mitochondrial membrane permeabilization when cells were challenged with the estrogen antagonist’s tamoxifen or fulvestrant [74]. The gene discussed is ESR1; the disease is breast carcinoma.